View printer-friendly version
« Back
November 08, 2005 11:53 a.m.
Teva Reports Third Quarter 2005 Results
Jerusalem, Israel, November 8, 2005 -

Third Quarter 2005 Highlights

  •   Net Income $267 million, up 6 %
  •   Net Sales $1.32 billion, up 6 %
  •   Copaxone® (in market) Sales $307 million, up 27 %
  •   Cash flow from operations $385 million
  •   EPS $0.40, up 8 %

    Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today reported results for the quarter ended September 30, 2005.

    Net income for the third quarter of 2005 was $267 million or $0.40 per share, an increase of 6% and 8%, respectively over the third quarter of 2004.

    Net Sales for the third quarter increased 6% over the comparable quarter last year to $1,317 million. Pharmaceutical sales accounted for 89% of total sales in the third quarter.

    Mr. Israel Makov, Teva's President and CEO, commented: "This has been an excellent and eventful quarter for Teva, with strong performances from all of our business units, record-breaking sales of Copaxone®, and the highly successful launch of Fexofenadine (generic Allegra®). Once again we demonstrated how we can leverage our unique business model to achieve continuous, profitable growth." He added, "We are especially excited about our acquisition of Ivax, which is proceeding very much on track."

    North American pharmaceutical sales (including Copaxone®) for the third quarter accounted for 60% of the Company's total pharmaceutical sales and reached $708 million, compared to $719 million in the third quarter of 2004. This quarter included the successful U.S. generic launch of Fexofenadine, as well as Medroxyprogesterone PFS. Higher sales of Copaxone® in the U.S. and higher overall pharmaceutical sales in the Canadian market partially offset the lower U.S. generic sales.

    As of today, 145 product applications are awaiting final FDA approval, representing annual branded U.S. sales of $97 billion. Teva believes it is the first to file on 39 of these applications relating to products whose annual U.S. branded sales total over $25 billion.

    Pharmaceutical sales in Europe (including Copaxone®) for the third quarter accounted for 29% of the Company's total pharmaceutical sales and increased 24% to $342 million compared to the prior year's quarter. This increase was primarily due to sales of products that were not sold in the comparable quarter including Alendronate, Paclitaxel and Atorvastatin, higher Copaxone® sales as well as the effect of the Dorom acquisition.

    Quarterly global in-market sales of Copaxone® increased 27% over the third quarter of 2004 to $307 million. U.S. in-market sales increased by 27% to $206 million. According to IMS, Copaxone® continued to lead the US market in both total and new prescriptions. As of September 2005 our NRx market share in the U.S. was 32.5% and our TRx market share was 32.9%. In-market sales outside the U.S., mainly in Europe and Canada, increased by 28% to $101 million.

    Agilect®/Azilect®- Azilect® was launched in Israel in March 2005 and is now also available in the U.K., Ireland, Germany, Austria, Denmark and Finland. The product is on track to be launched progressively in additional European countries throughout the remainder of the year and in 2006.
    In the U.S., Teva continues to work with the FDA to resolve the remaining issues regarding final marketing approval of Agilect®.

    Total API sales, including internal sales to Teva's pharmaceutical businesses increased slightly to $265 million. API sales to third parties reached $138 million compared to $146 million in the third quarter of 2004.

    Gross profit margin was 47.0% in the third quarter of 2005 compared with 47.3% for the third quarter of 2004 and 47.0%, excluding one time acquisition related items, for fiscal year 2004. Gross profit margins this quarter remained within our guidance range of 45%-48%, with quarterly margins varying due to shifts in product and market mix.

    Gross R&D spending for the quarter increased 2% to $97 million. Net R&D (after third party participations) increased at the same rate to $92 million.

    Selling, General and Administrative (SG&A) expenses, reached $214 million (16.2% of net sales) compared to $182 million (14.6% of net sales) in the third quarter of 2004. The year-over-year increase in SG&A was primarily the result of the profit sharing agreement with Barr for the sales of Fexofenadine.

    The tax rate for the third quarter was 15.9%, which adjusts for our current best estimated tax rate for the whole year, which now stands at 19.6%, compared with the 21.5% we have provided for in the first two quarters. This change reflects a different mix of income sources and slightly lower tax rates in certain countries.

    Cash flow generated from operating activities for the third quarter of 2005 was $385 million, compared to $391 million in the third quarter of 2004. As of September 30, 2005 cash and marketable securities totaled $1.8 billion.

    Shareholders Equity as of September 30, 2005 reached $5.6 billion, reflecting an increase of $257 million over June 30, 2005.

    IVAX acquisition - On July 25, 2005, Teva and IVAX Corporation (AMEX: IVX) announced that they had signed a definitive agreement providing for the acquisition of IVAX by Teva. On October 27, shareholders of both companies overwhelmingly approved (98%) the respective proposals submitted to them relating to the acquisition. The companies continue to expect that the transaction will close in late 2005 or early 2006, following completion of the Hart-Scott Rodino clearance process, the obtaining of other required antitrust approvals and the satisfaction of all other closing conditions contained in the merger agreement.

    The Board of Directors, at its meeting on November 7, 2005, declared a interim cash dividend for the third quarter of 2005 of NIS 0.30 (approx. $0.06 according to the rate of exchange on November 6, 2005) per ADR. The record date will be November 15, 2005 (the ex-date will be November 16, 2005), and the payment date will be November 30, 2005. Tax will be withheld at a rate of 18%.

    Conference Call
    Teva will host a conference call to discuss the Company's third quarter results on Tuesday, November 8, 2005 at 08:30 a.m. EST. The call will be webcast and can be accessed through the Company's website at Following the conclusion of the call, a replay of the webcast will be available within 24 hours at the Company's web site. Alternatively, a replay of the call can be accessed until November 15, 2005 at midnight (ET), by calling 1-(877) 660-6853 in the U.S. or 1-(201) 612-7415 outside the U.S. The pass code to access the replay is: Account #: 3055 and Conference ID#: 174992.

    Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva's sales are in North America and Europe.

    Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include whether and when the proposed acquisition of IVAX Corporation will be consummated and the terms of any conditions imposed in connection with such closing, the terms and conditions of the financing utilized by Teva for the IVAX acquisition, Teva's ability to rapidly integrate IVAX's operations and achieve expected synergies, Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a final court decision, including that relating to the generic versions of Neurontin® and Allegra®, the effects of competition on Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations outside the United States that may be adversely affected by terrorism or major hostilities, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.